People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ECM Therapeutics, Inc. | — | Biotechnology | Series B | $35.2M | $1.4B | 2018 |
| Three Rivers Pharmaceuticals Llc | — | Pharmaceuticals | Series A | $6.6M | $203.0M | 2009 |
Paul F. Fagan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul F. Fagan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Fisher | 1 | 2 |
| Christine F. Sheehy | 1 | 1 |
| Jenna F. Dziki | 1 | 1 |
| Stephen F. Badylak | 1 | 1 |
| George F. Hussey | 1 | 1 |
| Lindsey F. Saldin | 1 | 1 |
| PATRICK L KERRISH | 1 | 1 |
| DONALD J KERRISH | 1 | 1 |
| CHRISTINE E SHEEHY | 1 | 1 |
| Katie F. Collins | 1 | 1 |
| BETTY SUE RICH | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.